期刊文献+

雌激素及促卵泡激素测定对女性肿瘤绝经判断的意义 被引量:1

Determination of estrogen and follicle stimulating hormone on the perimenopausal diagnosis of female cancer patients
下载PDF
导出
摘要 目的:探讨女性肿瘤患者各个年龄组雌激素(E2)及促卵泡激素(FSH)水平及关系。观察围绝经期雌激素水平及变化趋势。评价E2、FSH在围绝经期诊断中的价值。方法:用电化学发光法检测1030例不同年龄女性肿瘤患者的E2、FSH值。结果:1030例女性肿瘤患者中各个年龄组的E2水平波动幅度不同。51岁组与50岁组比较差异有显著性(P<0.05),FSH水平平稳,各个年龄组研究比较差异无显著性(P>0.05)。结论:女性肿瘤患者绝经期的判断要考虑多方面因素,除了年龄、E2、FSH、E2/FSH值的变化,还要注意周期的变化,检测的连续性以便观察体内激素水平变化及临床用药。 Objective: To explore level of estrogen (E2) and follicle - stimulating hormone (FSH) in female cancer patients. Methods:The levels of E2 and FSH in 1030 female cancer patients of different ages were measured by electrochemiluminescence. Results:E2 level fluctuations in 1030 female cancer patients of each age group were different. Compared with the 51 - year - old group and the 50 - year - old group, the difference was significant (P 〈 0.05). FSH level was stable, each age group had no significant differences (P 〉 0.05 ). Conclusion:Various factors must be considered in the perimenopausal diagnosis, including changes of age, E2, FSH, E2/FSH value, cycle and the continuity of test, in order to observe the changes in hormone levels.
出处 《现代肿瘤医学》 CAS 2014年第1期169-171,共3页 Journal of Modern Oncology
关键词 雌激素 促卵泡激素 女性肿瘤 绝经判断 estrogen(E2) follicle -stimulating hormone(FSH) female cancer perimenopausal diagnosis
  • 相关文献

参考文献2

二级参考文献20

  • 1程国钧,刘建立.绝经后妇女雌激素替代治疗[J].中华妇产科杂志,1995,30(2):123-127. 被引量:150
  • 2[1]Early Breast Cancer Trialists'Collaborative Group(EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overdew of the randomized trials.Lancet,2005,365:1687
  • 3[2]R.Peto.ATLAS(adjuvant tamoxifen,longer against shoger):International randomized trial of 10 vs 5 years of adjuvant tamoxifen among 11 500 women-preliminary results.SABCS 2007,Abstract #48
  • 4[3]Coombes RC,Hall E,Gibson LJ,et al.Intergroup exemestane study:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med,2004,350(11):1081.
  • 5[4]ATAC ATAC Trialists'Croup.Results of the ATAC(arimidex,tamoxifen,alone or in combination)trial after completion of 5 years'adjuvant treatment for breast cancer.Lancet,2005,365:60
  • 6[5]Goss PE,Ingle JN,Martino S,et al.Updated analysis of the NCIC CTG MA.17 randomized placebo(P)controlled trial of letrozole(L)after five years of tamoxifen in postmenopausal women with early stage breast cancer.J Clin Oncol,2004,22:Abstract 847.
  • 7[6]Raimund Jakesz,Walter Jonat,Michael Gnant,et al,Switching of postmenopausal women with endocrlneresponsive early breast cancer to anastrozole after2 years'adjuvant tamoxifen:Combined results of ABCSG trial 8 and ARNO 95 trial Lancet,2005,366:4515
  • 8[7]Thrulimann B,Keshaviah A,Coates AS,et al,(Breast International Group 1-98 Collaborative Group.A comparisonof letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med,2005,353(26):2747
  • 9[8]Van de Velde CJ,Jones SE,Seynacve C,et al.Patterns of care in patients included in the TEAM (tamoxifen and exemestane adjuvant muhicentre)trial.Differences among the participating countries.28th Annual San Antonio Breast Cancer Symposium,2005,3057:S143
  • 10[9]Per E.Lonning,Jürgen Geisler,Lars E.Krag,et al.Effects of exemestane administered for 2 years versus placebo on bone mineral density,bone biomarkers,and plasma lipids in patients with sursically resected early breast cancer.J Clin Oncol,2005,23:5126

共引文献12

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部